scholarly journals Plasma elafin, cathelicidin, and α-defensins are increased in paediatric inflammatory Crohn’s disease and reflect disease location

2021 ◽  
Vol 17 (4) ◽  
pp. 1114-1117
Author(s):  
Andrzej Wędrychowicz ◽  
Przemysław Tomasik ◽  
Kinga Kowalska-Duplaga ◽  
Stanisław Pieczarkowski ◽  
Krzysztof Fyderek
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Antimicrobial Peptides ◽  
Inflammatory Phenotype ◽  
Beta Defensins ◽  
Disease Location

IntroductionThe aim of our study was to assess antimicrobial peptides in children with Crohn’s disease (CD).Material and methodsPlasma elafin, cathelicidin, alpha and beta-defensins were assessed in 35 children with CD using immunoassays. Phenotype and location of CD were assessed based on the results of endoscopic and radiology studies.ResultsWe found increased elafin, cathelicidin and alpha-defensins in children with inflammatory phenotype as compared to stricturising and penetrating phenotypes of CD. Additionally, we found increased elafin and cathelicidin in colonic location and alpha defensins in ileal CD locations.ConclusionsAssessing antimicrobial peptides may be helpful in estimating of phenotype and location of CD lesions.

Increased Production of Retinoic Acid by Intestinal Macrophages Contributes to Their Inflammatory Phenotype in Patients With Crohn's Disease

2014 ◽  
Vol 146 (5) ◽  
pp. 1278-1288.e2 ◽  
Author(s):  
Theodore J. Sanders ◽  
Neil E. McCarthy ◽  
Edward M. Giles ◽  
Katherine L.M. Davidson ◽  
Myriam L.R. Haltalli ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Retinoic Acid ◽  
Crohn's Disease ◽  
Inflammatory Phenotype

scholarly journals P615 Efficacy of vedolizumab in patients with Crohn's disease may differ depending on the disease location: The UCLH experience

2018 ◽  
Vol 12 (supplement_1) ◽  
pp. S420-S421
Author(s):  
T Kumagai ◽  
M Vinayaga-Pavan ◽  
I Parisi ◽  
J Barragry ◽  
R Sundramoorthi ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Disease Location

scholarly journals Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study

2020 ◽  
Vol 26 (10) ◽  
pp. 1562-1571 ◽  
Author(s):  
Walter Reinisch ◽  
Remo Panaccione ◽  
Peter Bossuyt ◽  
Filip Baert ◽  
Alessandro Armuzzi ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Surrogate Marker ◽  
Fecal Calprotectin ◽  
Sensitivity Analyses ◽  
End Points ◽  
Predictive Values ◽  
Post Hoc Analysis ◽  
Post Hoc ◽  
Disease Location

Abstract Background CALM was a randomized phase 3 trial in patients with Crohn’s disease (CD) that demonstrated improved endoscopic outcomes when treatment was escalated based on cutoffs for inflammatory biomarkers, fecal calprotectin (FC), C-reactive protein (CRP), and CD Activity Index (CDAI) remission vs CDAI response alone. The purpose of this post hoc analysis of CALM was to identify drivers of treatment escalation and evaluate the association between biomarker cutoff concentrations and endoscopic end points. Methods The proportion of patients achieving CD Endoscopic Index of Severity (CDEIS) <4 and no deep ulcers 48 weeks after randomization was evaluated according to CRP <5 mg/L or ≥5 mg/L and FC <250 μg/g or ≥250 μg/g. Subgroup analyses were performed according to disease location, and sensitivity analyses were conducted in patients with elevated CRP and/or FC at baseline. The association between endoscopic end points and biomarker cutoffs was performed using χ 2 test. Results The proportion of patients who achieved the primary end point CDEIS <4 and no deep ulcers was significantly greater for those with FC <250 µg/g (74%; P < 0.001), with an additive effect for CRP <5 mg/L. The association of FC <250 µg/g with improved endoscopic outcomes was independent of disease location, although the greatest association was observed for ileocolonic disease. Fecal calprotectin <250 µg/g, CRP <5 mg/L, and CDAI <150 gave a sensitivity/specificity of 72%/63% and positive/negative predictive values of 86%/42% for CDEIS <4 and no deep ulcers 48 weeks after randomization. Conclusion This post hoc analysis of CALM demonstrated that a cutoff of FC <250 µg/g is a useful surrogate marker for mucosal healing in CD.

scholarly journals P128 Diagnostic accuracy of faecal calprotectin in Crohn's disease – Does disease location matter?

2017 ◽  
Vol 11 (suppl_1) ◽  
pp. S141-S142
Author(s):  
E. Simon ◽  
R. Wardle ◽  
A.A. Thi ◽  
J. Eldridge ◽  
S. Samuel ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Diagnostic Accuracy ◽  
Faecal Calprotectin ◽  
Disease Location

Su1805 - Fecal Calprotectin is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location

2018 ◽  
Vol 154 (6) ◽  
pp. S-590-S-591 ◽  
Author(s):  
Anthony Buisson ◽  
Wing Yan Mak ◽  
Michael J. Andersen ◽  
Donald Lei ◽  
Joel R. Pekow ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Fecal Calprotectin ◽  
Highly Effective ◽  
Disease Location

scholarly journals P606 Exclusive enteral nutrition with a polymeric diet is efficacious in inducing remission in adults with active Crohn’s disease

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S505-S508
Author(s):  
P Kakkadasam Ramaswamy ◽  
R Mutsekwa ◽  
X Lan ◽  
Y Chen ◽  
R Angus ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Enteral Nutrition ◽  
Induction Therapy ◽  
Final Analysis ◽  
Adult Patients ◽  
Current Smoking ◽  
Exclusive Enteral Nutrition ◽  
Male Sex ◽  
Disease Location

Abstract Background Exclusive Enteral nutrition (EEN) is not routinely used as induction therapy for adults with active Crohn’s disease (CD)due to limited adherence and palatability. The aim of this study was to assess the efficacy, tolerability and safety of EEN in adult patients with CD. Methods Retrospective analysis of data from patients with active CD who underwent induction therapy with EEN at a single centre from January 2018 to July 2019. All patients who completed at least 4 weeks of polymeric EEN diet were included in the final analysis. Primary Endpoint (PE) was steroid-free clinical remission (CDAI ≤150) or response (100 point decrease in CDAI) at the end of therapy. Secondary endpoint (SE) was achievement of biochemical remission (CRP <5 mg/l or Calprotectin <150 μg/g) at 8–10 weeks. Results Sixty-three patients were initiated on EEN, 50 patients who completed at least 4 weeks of EEN were included in the final analysis. Mean age was 42.4 years, 25 (50%) were females. Mean CDAI score at baseline was 260. Forty per cent of patients were on concurrent biologics and 66.6% were on concurrent immunomodulators. At the completion of EEN, 72% (36/50) of patients achieved PE (29 remission, 7 response). SE was achieved in 65.7% (23/35) of patients. EEN duration ≥ 6 weeks was more likely to achieve PE (75% vs. 55.5%, OR 2.7, P 0.01) and SE (71% vs. 25%, OR 7.3, P 0.001).EEN duration < 6 weeks and current smoking were less likely to achieve PE and SE. Patients with concomitant steroid use at baseline had PE of 77.7% (vs. 68.8% with EEN alone; OR 0.9, P 0.5), and SE of 66.6% (vs. 60.9% with EEN alone, OR 0.77, P 0.74). Disease location, behaviour, sex, disease duration, concurrent biologic use or concurrent immunomodulator use did not affect the PE or SE. Six patients reported adverse effects (3 nausea,2 diarrhoea,1 constipation). Male sex, ileal location, B2/B3 phenotype were more likely to complete a 6 week EEN course. Conclusion Polymeric EEN is well-tolerated, safe and efficacious in inducing remission in adults with active CD. EEN duration of ≥ 6 weeks has better outcomes. EEN alone or in combination with steroids induces remission in adult patients with active CD. Further controlled trials using polymeric EEN are necessary.

scholarly journals Inflammation and fibrosis in Crohn’s disease: location-matched histological correlation of small bowel ultrasound features

2020 ◽  
Author(s):  
Gauraang Bhatnagar ◽  
Manuel Rodriguez-Justo ◽  
Antony Higginson ◽  
Paul Bassett ◽  
Alastair Windsor ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Disease Location ◽  
Bowel Ultrasound ◽  
Ultrasound Features
Sign in / Sign up

Export Citation Format

Share Document